Radboudumc
The Department of Medical Imaging has a long-standing research line on the development and application of radiolabeled tracers for nuclear imaging and therapy. Within the department, there is a strong focus on translational research by collaborations between basic scientists and clinical researchers. Research includes molecular studies on the working mechanism of nuclear therapies, preclinical development of new imaging and therapeutic agents for cancer patients and clinical trials.
The department has excellent research facilities, including level B radionuclide laboratories and GMP radiolabeling facilities. Further a preclinical imaging center (
PRIME) with state-of-the art imaging facilities including microPET/CT, microSPECT/CT, IVIS fluorescence/bioluminescence and small-bore high-field MRI. The research group consists of approximately 30 researchers, including senior scientists, PhD students, medical doctors, and research technicians.
Radboudumc Welcome to Radboud university medical center (Radboudumc), where our research groups strive for innovative solutions that make impact on health and healthcare. We challenge the status quo to overcome current and future health challenges. Our goal is to shape the future of healthcare for generations to come. Our focus is on prevention, sustainability, and meaningful care, which we achieve through our in-depth understanding of disease mechanisms, clinical science, public health research, medical technology and data science. Our approach is centered on breakthroughs that can truly enhance personalized healthcare and public health.
At Radboudumc, a comprehensive range of research programs provide the compass for our research efforts. Each program has a clear goal, where collaboration within and outside our organization is highly valued. We integrate care, education and research in partnership with our patients to ensure that our research programs have significant impact on health and healthcare. We invite you to join us in our mission to create a healthy future for all.